Psychiatric illness and regression in individuals with Phelan-McDermid syndrome.


Journal

Journal of neurodevelopmental disorders
ISSN: 1866-1955
Titre abrégé: J Neurodev Disord
Pays: England
ID NLM: 101483832

Informations de publication

Date de publication:
12 02 2020
Historique:
received: 31 05 2019
accepted: 23 01 2020
entrez: 14 2 2020
pubmed: 14 2 2020
medline: 18 5 2021
Statut: epublish

Résumé

Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability, speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33 deletions or mutations affecting SHANK3, which codes for a critical scaffolding protein in excitatory synapses. SHANK3 variants are also known to be associated with an increased risk for regression, as well as for psychiatric disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS and to explore any relationship between psychiatric illness and regression after early childhood. Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample for comparison. The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases; 82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to 32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20 cases (53%). Triggers included infections, changes in hormonal status, and stressful life events. This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals with PMS.

Sections du résumé

BACKGROUND
Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability, speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33 deletions or mutations affecting SHANK3, which codes for a critical scaffolding protein in excitatory synapses. SHANK3 variants are also known to be associated with an increased risk for regression, as well as for psychiatric disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS and to explore any relationship between psychiatric illness and regression after early childhood.
METHODS
Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample for comparison.
RESULTS
The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases; 82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to 32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20 cases (53%). Triggers included infections, changes in hormonal status, and stressful life events.
CONCLUSIONS
This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals with PMS.

Identifiants

pubmed: 32050889
doi: 10.1186/s11689-020-9309-6
pii: 10.1186/s11689-020-9309-6
pmc: PMC7014655
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7

Subventions

Organisme : NINDS NIH HHS
ID : U54 NS092090
Pays : United States
Organisme : National Institute of Neurological Disease and Stroke
ID : R01NS105845-01
Pays : International
Organisme : Intramural NIH HHS
ID : ZIC MH002961
Pays : United States

Références

Am J Med Genet A. 2005 Aug 30;137(2):139-47
pubmed: 16059935
Hum Genet. 2014 Jul;133(7):847-59
pubmed: 24481935
Epilepsia. 2016 Oct;57(10):1651-1659
pubmed: 27554343
Mol Autism. 2014 Apr 25;5:30
pubmed: 25071925
Epilepsy Behav. 2018 Mar;80:312-320
pubmed: 29402632
Eur J Med Genet. 2019 Aug 27;:103751
pubmed: 31465867
Pediatrics. 2014 Sep;134(3):e903-18
pubmed: 25157020
J Autism Dev Disord. 2017 Apr;47(4):918-926
pubmed: 28074354
J Neurodev Disord. 2014;6(1):39
pubmed: 25784960
J Psychiatr Res. 2017 Aug;91:139-144
pubmed: 28346892
Mol Autism. 2018 Apr 27;9:31
pubmed: 29719671
Am J Med Genet A. 2018 Oct;176(10):2146-2159
pubmed: 29777584
Genes Brain Behav. 2016 Apr;15(4):395-404
pubmed: 26824576
Eur J Med Genet. 2012 Nov;55(11):625-9
pubmed: 22922660
Mol Syndromol. 2012 Jun;3(1):14-20
pubmed: 22855650
PLoS Genet. 2011 Jul;7(7):e1002173
pubmed: 21779178
Autism Res. 2018 Feb;11(2):212-222
pubmed: 29226600
J Neurodev Disord. 2017 Nov 10;9(1):37
pubmed: 29126394
Dev Med Child Neurol. 2019 Jul;61(7):847-851
pubmed: 30548468
J Autism Dev Disord. 2018 Mar;48(3):947-952
pubmed: 29164439
J Child Neurol. 2015 Aug;30(9):1147-52
pubmed: 25367918
BMC Psychiatry. 2015 May 07;15:107
pubmed: 25947967
Alzheimers Res Ther. 2019 Mar 21;11(1):26
pubmed: 30902060
Schizophr Res. 2016 Oct;176(2-3):378-386
pubmed: 27377978
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7863-8
pubmed: 20385823
Clin Neuropsychol. 2018 Aug - Oct;32(7):1226-1255
pubmed: 29265961
J Neurodev Disord. 2016 Apr 26;8:16
pubmed: 27118998
Neuropsychiatr Dis Treat. 2015 Apr 02;11:941-9
pubmed: 25897230
Neurosci Biobehav Rev. 2019 Mar;98:320-332
pubmed: 30832924
J Autism Dev Disord. 2013 Apr;43(4):817-28
pubmed: 22855372
Neurocase. 2018 Aug;24(4):227-230
pubmed: 30376408
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Mol Autism. 2019 Dec 24;10:50
pubmed: 31879555
Neurosci Biobehav Rev. 2016 Apr;63:207-22
pubmed: 26780584
Pediatr Neurol. 2010 Nov;43(5):307-15
pubmed: 20933172
Eur J Med Genet. 2016 Sep;59(9):436-43
pubmed: 27519580
Am J Med Genet A. 2010 Mar;152A(3):573-81
pubmed: 20186804
Nat Genet. 2007 Jan;39(1):25-7
pubmed: 17173049
Neurobiol Aging. 2017 Oct;58:68-76
pubmed: 28715661
J Med Genet. 2003 Aug;40(8):575-84
pubmed: 12920066
Int Rev Neurobiol. 2006;72:233-44
pubmed: 16697301
J Neurodev Disord. 2015;7(1):9
pubmed: 25810793
Mol Autism. 2013 Jun 11;4(1):18
pubmed: 23758760
J Alzheimers Dis. 2018;61(2):631-644
pubmed: 29254096
Am J Med Genet A. 2013 Jan;161A(1):158-61
pubmed: 23166010

Auteurs

Teresa M Kohlenberg (TM)

Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA. tesik@rcn.com.

M Pilar Trelles (MP)

Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Brittany McLarney (B)

Phelan-McDermid Syndrome Foundation, Osprey, FL, USA.

Catalina Betancur (C)

Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, Paris, France.

Audrey Thurm (A)

Neurodevelopmental and Behavioral Phenotyping Service, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Alexander Kolevzon (A)

Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH